Heparin-induced thrombocytopenia associated with low-molecular-weight heparin: clinical feature analysis of cases and pharmacovigilance assessment of the FAERS database

被引:3
|
作者
Liu, Leping [1 ]
Zheng, Hong [2 ]
Chen, Shanshan [3 ]
Wang, Shengfeng [4 ,5 ,6 ]
Yang, Minghua [1 ,6 ,7 ]
机构
[1] Cent South Univ, Xiangya Hosp 3, Dept Pediat, Changsha, Hunan, Peoples R China
[2] Cent South Univ, Xiangya Hosp, Dept Pediat, Changsha, Hunan, Peoples R China
[3] Cent South Univ, Hunan Canc Hosp, Dept Pharm, Affiliated Canc Hosp,Xiangya Sch Med, Changsha, Hunan, Peoples R China
[4] Cent South Univ, Xiangya Hosp 3, Dept Pharm, Changsha, Hunan, Peoples R China
[5] Cent South Univ, Xiangya Hosp 3, Postdoctoral Res Stn Clin Med, Changsha, Hunan, Peoples R China
[6] Cent South Univ, Xiangya Hosp 3, MOE Key Lab Rare Pediat Dis, Changsha, Hunan, Peoples R China
[7] Cent South Univ, Xiangya Hosp 3, Hunan Clin Res Ctr Pediat Canc, Changsha, Hunan, Peoples R China
基金
中国国家自然科学基金;
关键词
low-molecular-weight heparin; heparin-induced thrombocytopenia; characteristics; treatments; pharmacovigilance; ENOXAPARIN-INDUCED THROMBOCYTOPENIA; VENOUS THROMBOEMBOLISM; PULMONARY-EMBOLISM; SKIN NECROSIS; PATIENT; RIVAROXABAN; MANAGEMENT; THROMBOSIS; ARTERIAL; FONDAPARINUX;
D O I
10.3389/fphar.2023.1247253
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Unfractionated heparin (UFH) and low-molecular-weight heparin (LMWH) are commonly used anticoagulants for the management of arterial and venous thromboses. However, it is crucial to be aware that LMWH can, in rare cases, lead to a dangerous complication known as heparin-induced thrombocytopenia (HIT). The objective of this study was to evaluate the pharmacovigilance and clinical features of HIT associated with LMWH, as well as identify treatment strategies and risk factors to facilitate prompt management.Methods: We extracted adverse event report data from the FDA Adverse Event Reporting System (FAERS) database for pharmacovigilance assessment. Case reports on LMWH-induced thrombocytopenia dated up to 20 March 2023 were collected for retrospective analysis.Results: Significantly elevated reporting rates of HIT were shown in adverse event (AE) data of LMWHs in the FAERS database, while tinzaparin had a higher proportional reporting ratio (PRR) and reporting odds ratio (ROR) than other LMWHs, indicating a greater likelihood of HIT. Case report analysis indicated that a total of 43 patients showed evidence of LMWH-induced thrombocytopenia with a median onset time of 8 days. Almost half of the events were caused by enoxaparin. LMWHs were mainly prescribed for the treatment of embolism and thromboprophylaxis of joint operation. Patients with a history of diabetes or surgery appeared to be more susceptible to HIT. Clinical symptoms were mostly presented as thrombus, skin lesion, and dyspnea. Almost 90% of the patients experienced a platelet reduction of more than 50% and had a Warkentin 4T score of more than 6, indicating a high likelihood of HIT. In all patients, LMWHs that were determined to be the cause were promptly withdrawn. Following the discontinuation of LMWHs, almost all patients were given alternative anticoagulants and eventually achieved recovery.Conclusion: LMWH-induced thrombocytopenia is rare but serious, with increased risk in patients with diabetes or a surgical history. Prompt recognition and management are crucial for the safe use of LMWHs.
引用
收藏
页数:11
相关论文
共 50 条
  • [31] Heparin-induced thrombocytopenia after elective hip replacement and prophylaxis of venous thromboembolism with low molecular-weight heparin
    Marx, A
    Huhle, G
    Hoffmann, U
    Wang, LC
    Schüle, B
    Jani, L
    Harenberg, J
    ZEITSCHRIFT FUR ORTHOPADIE UND IHRE GRENZGEBIETE, 1999, 137 (06): : 536 - 539
  • [32] Thrombocytopenia Due to Direct Oral Anticoagulation and Low-Molecular-Weight Heparin
    Tucker, Madeline
    Padarti, Akhil
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2021, 13 (10)
  • [33] Cross-reactivity study of low molecular weight heparins and heparinoid in heparin-induced thrombocytopenia
    Vun, CM
    Evans, S
    Chong, BH
    THROMBOSIS RESEARCH, 1996, 81 (05) : 525 - 532
  • [34] Incidence of Heparin-Induced Thrombocytopenia in Patients Treated with Unfractionated Versus Low Molecular Weight Heparin after Acute Coronary Syndrome
    Ahmed, Shafique
    Ahmad, Shehzad
    Kashif, Mohammad
    PAKISTAN JOURNAL OF MEDICAL & HEALTH SCIENCES, 2013, 7 (01): : 67 - 69
  • [35] Update on the clinical use of the low-molecular-weight heparin, parnaparin
    Camporese, Giuseppe
    Bernardi, Enrico
    Noventa, Franco
    VASCULAR HEALTH AND RISK MANAGEMENT, 2009, 5 : 819 - 831
  • [36] Mimic of massive pulmonary embolism: heparin-induced thrombocytopaenia (HIT)-associated anaphylactoid reactions following subcutaneous low molecular weight heparin
    McGahan, Natalie
    Ziller, Clemens
    Phipps, William
    BMJ CASE REPORTS, 2024, 17 (10)
  • [37] Low-molecular-weight heparin-induced osteoporosis and osteoporotic fractures: A myth or an existing entity?
    Lefkou, E.
    Khamashta, M.
    Hampson, G.
    Hunt, B. J.
    LUPUS, 2010, 19 (01) : 3 - 12
  • [38] Should patients be informed about the risk of heparin-induced thrombocytopenia before prolonged low-molecular-weight heparin thromboprophylaxis post-trauma/orthopedic surgery?
    Lubenow, Norbert
    Hinz, Peter
    Ekkernkamp, Axel
    Greinacher, Andreas
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2007, 79 (03) : 187 - 190
  • [39] Low molecular weight heparin-induced skin necrosis—a systematic review
    A. E. Handschin
    O. Trentz
    H. J. Kock
    G. A. Wanner
    Langenbeck's Archives of Surgery, 2005, 390 : 249 - 254
  • [40] ANTICOAGULANT WITH THE LOW-MOLECULAR-WEIGHT HEPARINOID ORG-10172 (ORGARAN(R)) DURING HEMODIALYSIS IN A PATIENT WITH HEPARIN-INDUCED THROMBOCYTOPENIA
    MAHUL, P
    RAYNAUD, J
    FAVRE, JP
    JOSPE, R
    DECOUSUS, H
    AUBOYER, C
    ANNALES FRANCAISES D ANESTHESIE ET DE REANIMATION, 1995, 14 (01): : 29 - 32